无效造血及其治疗
无效造血的特征是促红细胞生成素驱动的早期红系前体细胞扩增,伴晚期前体细胞凋亡,是β-地中海贫血、遗传性铁粒幼细胞性贫血、先天性红细胞生成不良性贫血及部分亚型骨髓增生异常综合征(MDS)贫血的主要机制。铁限制策略在β-地中海贫血小鼠模型中可减少无效造血;Luspatercept已获批用于需定期红细胞输注的成人β-地中海贫血及伴环形铁粒幼细胞的MDS患者贫血。
要点
- 无效造血由促红细胞生成素驱动早期红系前体扩增及晚期前体凋亡所致。
- 遗传性无效造血贫血因红系因子释放抑制hepcidin生成而伴实质铁过载。
- Luspatercept已获批用于需定期输血的成人β-地中海贫血及伴环形铁粒幼细胞的MDS贫血。
核心结论
- 靶向无效造血的新疗法正在开发中,Luspatercept已获批用于β-地中海贫血和伴环形铁粒幼细胞的MDS贫血,但其长期有效性和安全性仍需评估。
研究设计与样本
- 综述,总结无效造血的机制及靶向治疗进展。
主要发现
- 无效造血的特征是促红细胞生成素驱动的早期红系前体细胞扩增,伴晚期前体细胞凋亡。
- 该机制是β-地中海贫血、遗传性铁粒幼细胞性贫血、先天性红细胞生成不良性贫血及部分亚型MDS贫血的主要原因。
- 遗传性无效造血贫血因红系因子释放抑制hepcidin生成导致实质铁过载,也被定义为铁负荷性贫血。
- 在β-地中海贫血小鼠模型中,通过增强hepcidin活性或抑制ferroportin功能限制铁可减少无效造血。
- Luspatercept是一种转化生长因子-β配体陷阱,抑制SMAD2/3信号,基于临床前和临床研究已获批用于需定期红细胞输注的成人β-地中海贫血及伴环形铁粒幼细胞(多数携带体细胞SF3B1突变)的MDS患者的输血依赖性贫血。
局限性
- Luspatercept在β-地中海贫血和MDS中的长期有效性和安全性仍需评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The erythroid marrow and circulating red blood cells (RBCs) are the key components of the human erythron. Abnormalities of the erythron that are responsible for anemia can be separated into 3 major categories: erythroid hypoproliferation, ineffective erythropoiesis, and peripheral hemolysis. Ineffective erythropoiesis is characterized by erythropoietin-driven expansion of early-stage erythroid precursors, associated with apoptosis of late-stage precursors. This mechanism is primarily responsible for anemia in inherited disorders like β-thalassemia, inherited sideroblastic anemias, and congenital dyserythropoietic anemias, as well as in acquired conditions like some subtypes of myelodysplastic syndrome (MDS). The inherited anemias that are due to ineffective erythropoiesis are also defined as iron-loading anemias because of the associated parenchymal iron loading caused by the release of erythroid factors that suppress hepcidin production. Novel treatments specifically targeting ineffective erythropoiesis are being developed. Iron restriction through enhancement of hepcidin activity or inhibition of ferroportin function has been shown to reduce ineffective erythropoiesis in murine models of β-thalassemia. Luspatercept is a transforming growth factor-β ligand trap that inhibits SMAD2/3 signaling. Based on preclinical and clinical studies, this compound is now approved for the treatment of anemia in adult patients with β-thalassemia who require regular RBC transfusions. Luspatercept is also approved for the treatment of transfusion-dependent anemia in patients with MDS with ring sideroblasts, most of whom carry a somatic SF3B1 mutation. While the long-term effectiveness and safety of luspatercept need to be evaluated in β-thalassemia and MDS, defining the molecular mechanisms of ineffective erythropoiesis in different disorders might allow the discovery of new effective compounds.
引用
- Cazzola M. Ineffective erythropoiesis and its treatment. Blood. 2022. PMID: 34932791. doi:10.1182/blood.2021011045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。